Chart shows breakout coming. Closed above resistance. Investor conf. wednesday. 15.00 target and lead drug phase III with safety profile that is superior to anything on the market for treatment up to 6 Million diabetes-related kidney disease. Own 100% of rights.
I like this one too. Been in it for a while. Chart looks good, volume picking up. 15.00 target. Good safety review on lead drug. 6 Million affected without a good treatment / side effect profile until now.